ESMO Breast 2024 | Future developments in lobular carcinoma: targeting E-cadherin defects

Jason Mouabbi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses ongoing and future trials in lobular carcinoma, focusing on targeting the defective E-cadherin molecule, a consistent feature in this type of cancer. He highlights a new study exploring the use of ROS1 inhibitors, commonly used in non-small cell lung cancer, for treating lobular carcinoma. This interview took place at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.